Zynex Inc., Amber International Holding, and Pasithea Therapeutics are the 3 Penny Stocks to watch on November 27, 2025, based on TipRanks’ Penny Stock Screener tool. Penny stocks are shares usually priced at $5 or below and represent companies with a market value under $300 million.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The Penny Stock Screener allows investors to identify stocks by applying a variety of filters, including Sector, Price Target Upside, Smart Score, Analyst Consensus, Dollar Volume, and Price Change.
We leveraged the tool to identify the top three penny stocks with the highest Dollar Volume as of market close on November 26, 2025. Dollar Volume refers to the total value of shares traded in a day, calculated by multiplying the number of shares traded by the stock’s price.
1. Zynex Inc. (ZYXI) – Zynex is a MedTech company that develops, manufactures, and sells non-invasive electrotherapy devices used mainly for managing pain, aiding physical rehabilitation, diagnosing neurological conditions, and monitoring cardiac health. On November 26, ZYXI had a Dollar Volume of $224.62 million, while its stock price rocketed by 115%.
No specific news justifies the stock surge. However, ZYXI shares have been rising since November 20, gaining 198% over that period.
2. Amber International Holding (AMBR) – Amber International is a Singapore-based digital wealth management platform, offering institutional-grade crypto financial services and solutions. On Wednesday, AMBR had a Dollar Volume of $222.02 million, accompanied by a stock price surge of 56%.
Amber announced a $50 million share repurchase program alongside its Q3 2025 earnings results. The company surpassed both sales and earnings expectations for the third quarter.
3. Pasithea Therapeutics (KTTA) – Pasithea Therapeutics is a clinical-stage biotechnology company engaged in developing novel treatments for central nervous system (CNS) disorders and RASopathies. Yesterday, KTTA had a Dollar Volume of $169.09 million, while its stock price skyrocketed by 117%.
Pasithea announced that it received a grant of about $1 million from the ALS Association to study its drug PAS-004 in patients with ALS (amyotrophic lateral sclerosis). This funding will support a Phase 1 clinical trial to evaluate how effective, safe, and tolerable PAS-004 is for treating ALS.
To find more penny stocks like these, you can take a look at TipRanks’ Penny Stock Screener tool. It shows a list of all penny stocks, their price movement, and other vital data.